Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

New study asks patients preference on kidney cancer treatment

2012 ASCO Annual Meeting

Published: 2 Jun 2012

Views: 4204

Rating:

Save

Dr Bernard Escudier - Institut Gustave Roussy, Paris, France

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Bernard Escudier presented results from a randomised, double-blind study of patients with metastatic kidney cancer.

The study found that the quality of life differences patients experienced between two FDA-approved therapies were enough to demonstrate a strong preference for pazopanib over sunitinib.

Related Videos

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC

Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC ( Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Patient expectations and shared decision making in aRCC

Prof Manuela Schmidinger and Prof Ernst Agneter

Patient expectations and shared decision making in aRCC ( Prof Manuela Schmidinger and Prof Ernst Agneter )

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC

Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC ( Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure

Dr Charalampos Fragkoulis - General Hospital of Athens, Athens, Greece

Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure ( Dr Charalampos Fragkoulis - General Hospital of Athens, Athens, Greece )

More from ecancer